SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): February 22,
1996
DURAMED PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-15242 11-2590026
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
7155 East Kemper Road, Cincinnati, Ohio 45249 (513) 731-9900
(Address and telephone number, including area code, of principal
executive offices)
<PAGE>
INFORMATION TO BE INCLUDED IN THE REPORT
Items 1, 2, 3, 4, 6 and 8 are not applicable and are omitted from
this Report.
Item 5. Other Events
The Company's press release dated February 22, 1996 is
attached as Exhibit 99 hereto and is incorporated
herein by reference.
Item 7. Financial Statements, Pro Forma Financial
Information and Exhibits.
(a) Financial Statements of Business Acquired.
Not Applicable
(b) Pro Forma Financial Information.
Not Applicable
(c) Exhibits.
The following exhibit is filed with this Report on
Form 8-K:
Regulation S-K
Exhibit No. Exhibit
99 Press release dated
February 22, 1996
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
Date: February 28, 1996 DURAMED PHARMACEUTICALS, INC.
By /s/ Timothy J. Holt
Timothy J. Holt
Vice President-Finance
<PAGE>
Exhibit 99
FOR IMMEDIATE RELEASE
February 22, 1996
DURAMED COMMENTS REGARDING OPERATING RESULTS
AND CONJUGATED ESTROGENS
CINCINNATI -- E. Thomas Arington, Chairman and CEO of Duramed
Pharmaceuticals, Inc., announced today that operating results for
the fourth quarter 1995 and for the year ended December 31 will
be released in late March. The exact release date depends upon
the resolution of matters which may affect the results.
Based upon current information, Duramed anticipates it will
report positive earnings for the year but may report a loss for
the fourth quarter 1995. The gross profit for the fourth quarter
1995 decreased from the fourth quarter 1994, both with respect to
dollar amount and as a percentage of net revenue. Duramed cannot
predict whether the decrease during the fourth quarter of 1995 is
a one-time event. Results for the fourth quarter and the year
have been affected by the Company's continuing increased product
launch expenses for conjugated estrogens and other products. Mr.
Arington added Duramed remains optimistic regarding the approval
of its conjugated estrogens product.
On a separate matter, Duramed is continuing negotiations for the
acquisition of Hallmark Pharmaceuticals, Inc. The resolution of
these negotiations may result in a charge to fourth quarter
operating results. Hallmark Pharmaceuticals is a privately held
pharmaceutical development company headquartered in Somerset, New
Jersey, which is expected to add to Duramed's product pipeline.
Duramed Pharmaceuticals, Inc. manufactures and markets a line of
prescription generic drug products in tablet, capsule and liquid
forms to customers throughout the United States. Headquartered
in Cincinnati, Duramed is traded on the NASDAQ exchange under the
symbol DRMD.
